Evidence map›Paper›PMID 41461540›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2026

[Prediction and

Huiying Zhang, Qing Fan, Yihua Zhang, Mengchen Liu, Guozhen Cui

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huiying ZhangSchool of Bioengineering, Zhuhai Campus of Zunyi Medical University, Key Laboratory of Quality Control and Evaluation of Traditional Chinese and Ethnic Medicines, Administration for Market Regulation of Guizhou Province, Zhuhai 519041, Guangdong Province, China. yjsxz091202@163.com.
Qing FanDepartment of Basic Teaching, Zhuhai Campus of Zunyi Medical University, Zhuhai 519041, Guangdong Province, China.
Yihua ZhangSchool of Bioengineering, Zhuhai Campus of Zunyi Medical University, Key Laboratory of Quality Control and Evaluation of Traditional Chinese and Ethnic Medicines, Administration for Market Regulation of Guizhou Province, Zhuhai 519041, Guangdong Province, China.
Mengchen LiuSchool of Bioengineering, Zhuhai Campus of Zunyi Medical University, Key Laboratory of Quality Control and Evaluation of Traditional Chinese and Ethnic Medicines, Administration for Market Regulation of Guizhou Province, Zhuhai 519041, Guangdong Province, China.
Guozhen CuiSchool of Bioengineering, Zhuhai Campus of Zunyi Medical University, Key Laboratory of Quality Control and Evaluation of Traditional Chinese and Ethnic Medicines, Administration for Market Regulation of Guizhou Province, Zhuhai 519041, Guangdong Province, China. cgzum@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo predict potential indications for ginkgolide B (GB) based on network pharmacology strategies.

methodsGB targets were comprehensively identified by integrating data from the Therapeutic Target Database, the Comparative Toxicogenomics Database, and BindingDB, followed by further validation based on literature. A standardized disease-gene dataset was established by integrating data from the genome-wide association study and the Online Mendelian Inheritance in Man Database. The topological proximity between GB targets and disease modules within the human protein-protein interaction network was quantified using network proximity metrics, with statistical significance evaluated via

resultsTwelve potential GB targets were identified, and a disease-gene dataset encompassing 680 diseases was established. Network proximity analysis revealed significant associations between GB and 22 diseases, of which 11 had prior literature support. Disease classification indicated that the predicted indications of GB were primarily enriched in immune-mediated inflammatory diseases, with notable examples including juvenile idiopathic arthritis (

conclusionsThis study systematically predicted 22 potential indications for GB and confirmed its therapeutic potential for immune-mediated inflam-matory diseases through

Indexed as

GinkgolidesLactonesNetwork PharmacologyAnimalsCytokinesGenome-Wide Association StudyHumansMacrophagesMiceNitric OxideProtein Interaction MapsRAW 264.7 CellsCytokinesginkgolide BGinkgolidesLactonesNitric OxideDrug repositioningGinkgolide BImmune-mediated inflammatory diseaseIndicationNetwork pharmacologyNetwork proximitySystem biology

Identifiers

PMID41461540
PMCPMC13195737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.